Noramco presented testimony and answered questions at the Food and Drug Administration’s (FDA) Scientific Data and Information about Products Containing Cannabis or Cannabis-Derived Compounds, Part 15 Public Hearing.
Noramco and Willow Biosciences Inc. today announced they have entered into an exclusive Joint Development Agreement (“JDA”) to collaboratively develop a yeast-based biosynthesis platform for the production and distribution of cannabidiol.
Communication is key for Staff Sales & Operations (S&OP) Planner Jackie Johnson. She corresponds with personnel in various departments on the daily basis, collecting essential customer information which she uses to create efficient production plans to meet customer forecasts.
Making active pharmaceutical ingredients at an extraordinary level of quality is one of the most challenging milestones to reach within the pharmaceutical industry, but nobody does that better than the chemical engineers at Noramco. More specifically, process engineers, like Dan Hallow.
Noramco is participating in the Scientific Thought Leadership program at this year’s AAPS. Dr. Wen-Chun Zhang will be presenting a Chalk Talk on the topic of “The New Era of Ultra-Pure Synthetic Cannabinoids” on Tuesday, November 6th, 2018 from 10:30 am to 10:50.